BPC-157
Body Protection Compound 157
Evidence & Status
- Preliminary / Experimental
- Preliminary
At a Glance
A research peptide derived from a protective protein found in gastric juice, commonly studied for its potential roles in tissue healing and recovery. Most frequently explored in research involving tendons, ligaments, muscles, and the gastrointestinal tract.
Plain English
Researchers study BPC-157 because it appears to play a role in how the body initiates and sustains healing after injury. Scientists are particularly interested in its potential connections to tendon and ligament repair, gut lining health, and the control of inflammation. Much of the existing research has been conducted in animal models, and scientists continue to explore how these findings may relate to human biology. It is often discussed in recovery-focused research literature alongside other tissue-repair compounds.
Overview
A 15-amino-acid peptide sequence associated with gastric-juice research. Published evidence is predominantly preclinical; animal findings in tissue and gastrointestinal models have not established clinical efficacy or safety in people.
Research Summary
The available evidence base is primarily preclinical. Limited human exposure data exist: a small 2025 pilot study examined intravenous BPC-157 administration in two participants and reported no serious acute adverse events, but this study was too small to establish clinical efficacy, long-term safety, or a pharmacokinetic profile (Lee and Burgess 2025). No adequately powered, controlled human efficacy program was identified in this review, and animal findings should not be interpreted as established clinical benefit. A July 2026 Pharmacy Compounding Advisory Committee discussion was advisory only and does not constitute FDA approval or a final FDA determination.
Research Areas
- Tendon healing
- Gut health
- Neuroprotection
- Anti-inflammatory
- Muscle repair
Safety & Risks
Serious Risks
- Human safety, pharmacokinetics, and long-term outcomes have not been established
Reported Side Effects
- Nausea (uncommon)
- Injection site redness
- Dizziness (rare)
- Vivid dreams (anecdotal)
Legal Status by Region
- United States
- Not FDA approved. The HHS interim 503A policy describes conditional enforcement discretion for BPC-157 acetate in subcutaneous, intramuscular, oral and topical dosage forms, not unrestricted permission for BPC-157 free base. This is not proof of safety or effectiveness or blanket compounding legality. The Federal Register notice describes a draft, nonbinding policy; no effective date is asserted here. Conditions include a patient-specific prescription; a State-licensed pharmacy, Federal facility or licensed physician; the exact Appendix B identity and route; FDA-registered original API manufacture compliant with CGMP, valid COAs, required quality testing and supplier validation; reporting compounded products, serious adverse events and quality issues to FDA and relevant States; patient reporting instructions and labeling 'This is a compounded drug product. Not for resale.'; a single Appendix A active ingredient; formulation-specific documentation of adequate human oral bioavailability for oral products; only a 510(k)-cleared syringe if a delivery device is co-packaged or contains the drug; and all other applicable FD&C Act requirements. This is not a 503B authorization. The interim policy lasts until a final rule addresses the substance and may be revisited for safety or quality signals.
- United Kingdom
- Research only
- Australia
- Research only
- Canada
- Research only
Citations & Sources
- Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
Lee E, Burgess K · Alternative Therapies in Health and Medicine · 2025
PMID 40131143
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, including Appendices A and B
U.S. Department of Health and Human Services · HHS
- Public inspection notice: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (filed October 28, 2026; scheduled publication October 30, 2026; not an effective-date determination)
U.S. Department of Health and Human Services · Federal Register — Public Inspection
Regulatory FR Doc. 2026-22192